Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center

home / authors / hope-s-rugo-md-helen-diller-family-comprehensive-cancer-center

Articles

Tiffany Traina, MD

Guideline Recommendations for CIN Prophylaxis

Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center
October 22nd 2021

Current recommendations by the National Comprehensive Cancer Network on chemotherapy-induced neutropenia prophylaxis, with special considerations for managing patients with cancer during COVID-19.

Read More

Management of HR+ mBC: Key Prognostic Factors

Management of HR+ mBC: Key Prognostic Factors

Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center;Aditya Bardia, MD, MPH, Massachusetts General Hospital;Dejan Juric, MD, Massachusetts General Hospital;Nicholas McAndrew, MD, MSCE, UCLA Health;Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center
June 30th 2021

Considerations for approaching the treatment of HR-positive metastatic breast cancer through insights on key prognostic factors.

Read More

Role of Molecular Profiling in HR+ Metastatic Breast Cancer

Role of Molecular Profiling in HR+ Metastatic Breast Cancer

Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center;Aditya Bardia, MD, MPH, Massachusetts General Hospital;Dejan Juric, MD, Massachusetts General Hospital;Nicholas McAndrew, MD, MSCE, UCLA Health;Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center
June 30th 2021

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, discuss when it is appropriate to order molecular testing and the impact of testing on the treatment of HR-positive metastatic breast cancer.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need